Ruxolitinib for Graft-versus-Host Disease

"To make things as convenient as possible for potential enrollees, the 35 sites for this trial are situated in cities across the country. These include Tucson, Los Angeles, Duarte, and many others."

"As of now, 1098 clinical trials involving Ruxolitinib are ongoing with 216 of them being Phase 3 trials. The majority of these are situated in Philadelphia, but there are a total of 33800 locations running these tests."

"Ruxolitinib is most commonly used as treatment for psoriasis. It can also be used to treat a variety of other conditions like polyangiitis, newly diagnosed acute lymphoblastic leukaemia, and lung cancer."

"This trial is no longer looking for new participants. The clinical trial was first posted on 3/7/2018 and was last updated on 6/9/2022. For patients searching for other studies, there are 167 clinical trials actively recruiting participants with disease and 1098 studies for Ruxolitinib actively searching for patients."

"The primary outcome of this 168 day trial is to measure the efficacy of ruxolitinib compared to the best available therapy (BAT) in participants with moderate or severe SR-cGvHD. This will be done by assessing the overall response rate (ORR) at the Cycle 7 Day 1 Visit. Secondary outcomes include percentage of participants successfully tapered off all corticosteroids at Cycle 7 Day 1 and the pharmacokinetics parameters of CL/F and Vz/F of ruxolitinib."

"There is some evidence of efficacy from Phase 3 trials and multiple rounds of data supporting safety, so Power gave Ruxolitinib a safety score of 3."

"This study is not admitting new patients at this time. The listing for this clinical trial was first created on March 7th, 2018 and was last updated on June 9th, 2022. However, there are 167 other trials for patients with diseases and 1098 trials for Ruxolitinib that are still recruiting patients."